乳腺癌机器人对比传统保留乳头乳晕乳房切除术的术后并发症与手术结局:Meta分析
该系统综述与Meta分析纳入7项质量一般的研究共1674例患者,比较机器人保留乳头乳晕乳房切除术与传统术式。机器人组乳头坏死显著减少(OR 0.54,95%CI 0.30-0.96,P=0.03),但手术时间与住院时间显著增加,出血量显著减少;Clavien-Dindo III级并发症无统计学显著差异。
要点
- 机器人保留乳头乳晕乳房切除术较传统术式显著减少乳头坏死(OR 0.54,95%CI 0.30-0.96)。
- 机器人组手术时间平均增加58.81分钟,住院时间平均增加1.23天。
- 机器人组出血量平均减少53.18 ml,Clavien-Dindo III级并发症无统计学显著差异。
核心结论
- 机器人乳腺手术虽仍处于起步阶段,但可能成为乳腺外科的可选方案,其肿瘤学安全性仍需可靠评估。
研究设计与样本
- 系统检索从建库至2022年9月的文献,纳入比较机器人保留乳头乳晕乳房切除术与传统保留乳头乳晕乳房切除术的并发症及手术变量的研究。
- 共纳入7项质量总体一般的研究,涉及1674例患者。
主要发现
- Clavien-Dindo III级并发症在机器人保留乳头乳晕乳房切除术中减少但无统计学显著性(OR 0.60,95%CI 0.35-1.05)。
- 乳头坏死在机器人保留乳头乳晕乳房切除术中显著减少(OR 0.54,95%CI 0.30-0.96;P=0.03;I²=15%)。
- 手术时间在机器人组显著增加(平均差+58.81分钟,95%CI +28.19至+89.44分钟;P=0.0002)。
- 住院时间在机器人组显著增加(平均差+1.23天,95%CI +0.64至+1.81天;P<0.0001)。
- 出血量在机器人组显著减少(平均差-53.18 ml,95%CI -71.78至-34.58 ml;P<0.0001)。
关键数值与推荐
- 主要结局为并发症(Clavien-Dindo III级并发症、皮肤或乳头坏死、血清肿、血肿、感染、假体丢失、伤口裂开)与肿瘤学安全性(复发和切缘阳性)。
- 次要结局包括手术变量、住院时间、成本效益、学习曲线和美学结局。
临床怎么用
- 机器人保留乳头乳晕乳房切除术可能成为乳腺外科的可选方案,但原文结论同时指出其肿瘤学安全性仍需可靠评估。
- 作者认为未来研究应探究该术式对癌症患者的长期安全性。
局限性
- 纳入的7项研究质量总体为一般。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer is the most common cancer worldwide, with remarkable advances in early diagnosis, systemic treatments, and surgical techniques. Robotic nipple-sparing mastectomy has been trialled; however, the complication rates, surgical outcomes, and oncological safety of this approach remain obscure. METHODS: A systematic search of the literature was conducted from conception until September 2022. Studies examining complications and operative variables where robotic nipple-sparing mastectomy was compared with conventional nipple-sparing mastectomy were included. Primary study outcomes were complications (Clavien-Dindo grade III complications, skin or nipple necrosis, seroma, haematoma, infection, implant loss, and wound dehiscence) and oncological safety (recurrence and positive margins). The secondary outcomes included operative variables, length of stay, cost-effectiveness, learning curve, and aesthetic outcome. RESULTS: A total of seven studies of overall fair quality, involving 1674 patients, were included in the systematic review and meta-analysis. Grade 3 complications were reduced in robotic nipple-sparing mastectomy without statistical significance (OR 0.60 (95 per cent c.i. 0.35 to 1.05)). Nipple necrosis was significantly reduced in robotic nipple-sparing mastectomy (OR 0.54 (95 per cent c.i. 0.30 to 0.96); P = 0.03; I2 = 15 per cent). Operating time (mean difference +58.81 min (95 per cent c.i. +28.19 to +89.44 min); P = 0.0002) and length of stay (mean difference +1.23 days (95 per cent c.i. +0.64 to +1.81 days); P < 0.0001) were significantly increased in robotic nipple-sparing mastectomy, whereas the opposite was true for blood loss (mean difference -53.18 ml (95 per cent c.i. -71.78 to -34.58 ml); P < 0.0001). CONCLUSION: Whilst still in its infancy, robotic breast surgery may become a viable option in breast surgery. Nonetheless, the oncological safety of this approach requires robust assessment. Robotic nipple-sparing mastectomy has been tried, but it is still not clear how often complications happen or how much better it is for cancer patients than conventional nipple-sparing mastectomy. The aim of this study was to compare robotic nipple-sparing mastectomy with conventional nipple-sparing mastectomy. A thorough search of all articles was performed from the start to September 2022. The studies that compared robotic nipple-sparing mastectomy with conventional nipple-sparing mastectomy in terms of problems and surgical factors were included. Complications and cancer outcomes (recurrence and positive margins) were the most important things that the study looked at. Surgical time, blood loss, length of hospital stay, cost-effectiveness, learning curve, and patient-reported outcome measures were some of the other things that were studied. This systematic review and meta-analysis looked at seven studies with fair quality and included 1674 patients. Even though there were fewer major problems with robotic nipple-sparing mastectomy, the difference was not significant. In robotic nipple-sparing mastectomy, there was less nipple necrosis, but the overall time it took to operate was much longer and the cost was higher. The average amount of bleeding was less in robotic nipple-sparing mastectomy. The robotic nipple-sparing mastectomy method had a better patient-reported outcome and a steep learning curve. Robotic nipple-sparing mastectomy is a safe method, with fewer problems than other methods. Future studies should look into if it is safe for cancer patients in the long run.
引用
- Nessa A, Shaikh S, Fuller M, et al. Postoperative complications and surgical outcomes of robotic versus conventional nipple-sparing mastectomy in breast cancer: meta-analysis. Br J Surg. 2024. PMID: 37890072. doi:10.1093/bjs/znad336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。